Cargando…
Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells
Castration-resistant prostate cancer (CRPC) frequently develops after initial standard radiation and androgen deprivation therapy, leaving patients with limited further treatment options. Androgen receptor (AR) is a transcription factor that plays a key role in the initiation and progression of pros...
Autores principales: | Chopra, Harman, Khan, Zara, Contreras, Jamie, Wang, Herui, Sedrak, Abanob, Zhu, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814211/ https://www.ncbi.nlm.nih.gov/pubmed/29464071 http://dx.doi.org/10.18632/oncotarget.23569 |
Ejemplares similares
-
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019) -
Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen
por: Qin, Jiang-Jiang, et al.
Publicado: (2017) -
Controlling the Mdm2-Mdmx-p53 Circuit
por: Waning, David L., et al.
Publicado: (2010) -
Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012) -
Mdmx promotes genomic instability independent of p53 and Mdm2
por: Carrillo, Alexia M., et al.
Publicado: (2014)